XML 72 R54.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Acquisitions (Asset Acquisitions) (Details) - USD ($) $ in Millions | 1 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2023 | Oct. 31, 2023 | Aug. 31, 2023 | Feb. 28, 2022 | Dec. 31, 2021 | Mar. 31, 2021 | Jan. 31, 2021 | Dec. 31, 2022
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  |  |  |  | $ 333.8
Mablink Biosciences SAS |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Acquired IPR&D Expense | $ 256.6 |  |  |  |  |  |  |
Beam Therapeutics Inc. |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  | $ 216.3 |  |  |  |  |  |
DICE Therapeutics, Inc. (DICE) |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  | $ 1,915.5 |  |  |  |  |
Versanis Bio, Inc. (Versanis) |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  | 604.1 |  |  |  |  |
Emergence Therapeutics AG |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  | $ 406.5 |  |  |  |  |
BioMarin Pharmaceutical Inc. |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  | $ 110.0 |  |  |  |
Foghorn Therapeutics Inc. |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  | $ 316.6 |  |  |
Rigel Pharmaceuticals, Inc. |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  |  | $ 125.0 |  |
Precision Biosciences, Inc. |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  |  |  | $ 107.8 |

X
- Definition Payments for Asset Acquisitions + References No definition available. + Details
Name: | lly_PaymentsForAssetAcquisitions
Namespace Prefix: | lly_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5 + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_MablinkBiosciencesSASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_BeamTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_DICETherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_VersanisBioIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_EmergenceTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_BioMarinPharmaceuticalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_FoghornTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_RigelPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_PrecisionBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |